The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer.

Breast disease Pub Date : 2024-01-01 DOI:10.3233/BD-249000

Fitran Amansyah, Prihantono Prihantono, Firdaus Hamid, Salman Ardi Syamsu, John Pieter, Muhammad Faruk

{"title":"The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer.","authors":"Fitran Amansyah, Prihantono Prihantono, Firdaus Hamid, Salman Ardi Syamsu, John Pieter, Muhammad Faruk","doi":"10.3233/BD-249000","DOIUrl":null,"url":null,"abstract":"Background: Molecular subtyping of breast cancer cells is increasingly being developed as an initial step in selecting therapy and predicting the prognosis of breast cancer patients. During breast cancer, the molecular subtype of cancer cells can change. This study aimed to analyze the relationship between changes in the intrinsic subtype of breast cancer with metastasis and progression-free survival in breast cancer patients.Methods: This was a retrospective cohort study of patients diagnosed with breast cancer from 2016 to 2021. The molecular subtypes from the immunohistochemical examination results were recorded twice, and metastasis and progression-free survival (PFS) were recorded. The data were analyzed using the chi-square test and SPSS 26.Results: Of the 44 patients, 19 (43.2%) experienced a change in molecular subtype, and 25 (56.8%) did not. No significant relationship existed between changes in molecular subtype and metastasis (p = 0.405). No significant relationship existed between changes in molecular subtype and PFS (p = 0.900). A significant relationship was found between changes in the molecular subtype and PFS in the patients with changes in the molecular subtype (p = 0.022).Conclusions: Changes in the intrinsic subtype were associated with PFS in breast cancer patients. Patients with an intrinsic subtype that changed to triple-negative showed worse PFS.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"71-78"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091556/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-249000","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Molecular subtyping of breast cancer cells is increasingly being developed as an initial step in selecting therapy and predicting the prognosis of breast cancer patients. During breast cancer, the molecular subtype of cancer cells can change. This study aimed to analyze the relationship between changes in the intrinsic subtype of breast cancer with metastasis and progression-free survival in breast cancer patients.

Methods: This was a retrospective cohort study of patients diagnosed with breast cancer from 2016 to 2021. The molecular subtypes from the immunohistochemical examination results were recorded twice, and metastasis and progression-free survival (PFS) were recorded. The data were analyzed using the chi-square test and SPSS 26.

Results: Of the 44 patients, 19 (43.2%) experienced a change in molecular subtype, and 25 (56.8%) did not. No significant relationship existed between changes in molecular subtype and metastasis (p = 0.405). No significant relationship existed between changes in molecular subtype and PFS (p = 0.900). A significant relationship was found between changes in the molecular subtype and PFS in the patients with changes in the molecular subtype (p = 0.022).

Conclusions: Changes in the intrinsic subtype were associated with PFS in breast cancer patients. Patients with an intrinsic subtype that changed to triple-negative showed worse PFS.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

乳腺癌分子亚型的变化与转移和无进展生存期的关系。

背景：乳腺癌细胞的分子亚型越来越多地被开发出来，作为选择治疗方法和预测乳腺癌患者预后的第一步。在乳腺癌发病过程中，癌细胞的分子亚型会发生变化。本研究旨在分析乳腺癌内在亚型的变化与乳腺癌患者转移和无进展生存期之间的关系：这是一项回顾性队列研究，研究对象为2016年至2021年确诊的乳腺癌患者。两次记录免疫组化检查结果中的分子亚型，并记录转移和无进展生存期（PFS）。数据采用卡方检验和 SPSS 26 进行分析：结果：在 44 例患者中，19 例（43.2%）的分子亚型发生了变化，25 例（56.8%）没有发生变化。分子亚型变化与转移之间无明显关系（P = 0.405）。分子亚型变化与 PFS 之间无明显关系（p = 0.900）。在分子亚型发生变化的患者中，分子亚型的变化与 PFS 之间存在明显关系（p = 0.022）：结论：内在亚型的变化与乳腺癌患者的生存期有关。结论：固有亚型的变化与乳腺癌患者的生存期有关，固有亚型变为三阴性的患者生存期更短。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.